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Abstract A program for overlaying multiple ﬂexible mol-
ecules has been developed. Candidate overlays are generated
by a novel ﬁngerprint algorithm, scored on three objective
functions (union volume, hydrogen-bond match, and hydro-
phobic match), and ranked by constrained Pareto ranking. A
diverse subset of the best ranked solutions is chosen using an
overlay-dissimilaritymetric.Ifnecessary,thesolutionscanbe
optimised.Amulti-objectivegeneticalgorithmcanbeusedto
ﬁnd additional overlays with a given mapping of chemical
features but different ligand conformations. The ﬁngerprint
algorithm may also be used to produce constrained overlays,
in which user-speciﬁed chemical groups are forced to be
superimposed.Theprogramhasbeentestedonseveralsetsof
ligands, for each of which the true overlay is known from
protein–ligand crystal structures. Both objective and sub-
jective success criteria indicate that good results are obtained
on the majority of these sets.
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Introduction
Ligand-based drug design techniques such as pharmaco-
phore analysis [1] and 3D quantitative structure–activity
relationships (3D QSAR) [2] are widely used. They usually
require the alignment ofa setofligands known tobindtothe
same protein. When the protein structure is unknown, the
likelihood that a given overlay is correct can be judged by
the extent to which it places similar groups from different
ligands near tooneanother,andonthe energiesofthe ligand
conformations. If the ligands are ﬂexible, there can be an
enormous number of ways in which they could be overlaid.
The problem is therefore challenging. New molecular-
overlay algorithms continue to be published [3–16], sug-
gesting that the state of the art is not considered satisfactory.
In the absence of the protein structure, the molecular-
overlay problem is under-determined. Except in trivial
cases, it is therefore unreasonable to suppose that the
correct solution can be identiﬁed unambiguously. A more
realistic aspiration is to produce a small number of sig-
niﬁcantly different but credible alignments, one of which is
close to the truth. With this in mind, we have previously
investigated the use of a multiple-objective genetic algo-
rithm (MOGA) for molecular alignment and pharmaco-
phore elucidation [17–19]. Our method is designed to
produce several overlays of a set of ligands using Pareto
ranking [20]. Each represents a different trade-off between
the various objective functions measuring overlay quality,
such as strain energy, volume, and matching of hydrogen-
bond features. The generation of multiple diverse overlays
produces a range of pharmacophore hypotheses to test.
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DOI 10.1007/s10822-012-9573-yWhile results were promising, we were aware of several
opportunities for improvement. For example, some types of
hydrophobic features were not properly represented; the
scoring protocol sometimes underestimated the degree of
hydrogen-bond matching; clique detection was used to set
up starting overlays for optimisation by the MOGA, but
other approaches seemed worth investigating. We also
wished to make analysis of the results easier: if a molec-
ular-overlay program produces many possible solutions, it
can be time consuming to sift through the output. We
therefore wanted good measures of overlay similarity that
would enable solutions to be clustered, or mapped in low-
dimensional space. Finally, we decided to test the revised
algorithm on several new sets of ligands, including diverse
sets, typical of those used as input for pharmacophore
elucidation, and sets of relatively close homologues, such
as are used in 3D QSAR.
The outcome of our new work has been to change the
algorithm appreciably. A novel method has been developed
for generating promising overlays using bit-string manip-
ulations. The resulting overlays are scored using new
objective functions, Pareto-ranked, and a diverse subset of
the best-ranked solutions chosen using an overlay-dissim-
ilarity measure. Overlays can be reﬁned, subjected to a new
process we call ‘‘overlay multiplication’’, and mapped
using multidimensional scaling. The new algorithm has
been tested on 10 sets of ligands taken from protein–ligand
crystal structures in the Protein Data Bank (PDB) [21].
Methods
Organisation and overview
This section is organised as follows. We begin by deﬁning
key terms and summarising the molecular input required by
the program. We then describe how chemical features such
as hydrogen-bonding and hydrophobic groups are identi-
ﬁed and represented. This is followed by a description of
several scoring functions used to assess the quality of
solution overlays.
We then describe the search algorithm, the ﬁrst step of
which is overlay generation. This is a ﬁngerprint technique
which generates several thousand possible overlays using
bit-string manipulations. The second step, overlay ﬁltering,
uses the scoring functions referred to above, together with
overlay similarity calculations, to identify a diverse subset
of the best of the solutions that have been generated.
Optionally, some or all of these may be subjected to overlay
reﬁnement—an optimisation process to bring approxi-
mately aligned groups into closer alignment. Finally, a
procedure called overlay multiplication may be applied to
solutions of particular interest. This explores the geometric
variability of speciﬁc pharmacophore hypotheses, using a
MOGA to determine whether a particular superposition of
ligand chemical features can be achieved with more than
one set of ligand conformations. The overlay generation and
ﬁltering steps are critical: if they fail to produce good
overlays, it is unlikely that reﬁnement or multiplication will
rectify the problem. Conversely, overlays from the ﬁltering
step may be good enough that no reﬁnement or multipli-
cation is necessary.
The section ends with a description of how overlay
similarity can be quantiﬁed, and describes analytical
techniques for helping users understand the relationships
between different overlays.
Nomenclature
The molecules to be overlaid are divided into features such
as hydrogen-bond donors and acceptors, and hydrophobic
groups (hydrophobes). Each feature is represented by one or
moreﬁttingpointsplacedatstrategicpositions(forexample,
on a donor atom or at the centroid of a hydrophobe). A
cluster of ﬁtting points in an overlay, all representing the
same type of feature and each from a different ligand, con-
stitutes a pharmacophore point. If every ligand contributes,
it is a full pharmacophore point; otherwise it is a partial
pharmacophore point. The complete collection of pharma-
cophore points in an overlay (optionally rejecting partial
points involving less than a speciﬁed number of ligands) is
the pharmacophore hypothesis (or simply pharmacophore)
suggested by that overlay. The composition of the pharma-
cophore (that is, the ligand features that contribute to the
pharmacophore points) is the feature mapping.
Ligand preparation
The ligands must be built in the protonation states they are
expected to adopt at the protein binding site, as these are
not altered during overlaying. While this is a weakness in
the program, the numbers of ligands being overlaid will
usually be small enough to allow users to assign proton-
ation states manually. Indeed, given knowledge from in-
house chemistry, users may often be better placed to decide
on difﬁcult tautomeric issues than an algorithm. A set of
low-energy conformers must be calculated for each ligand.
We have used OMEGA [22] but other conformer genera-
tors should also be suitable.
Feature deﬁnition; ﬁtting-point placement
Two types of hydrophobic features are deﬁned, directional
and non-directional. The former are groups that are more
likely to form hydrophobic interactions in some directions
than others, such as aromatic rings [23] and amide
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123linkages. It may seem odd to deﬁne amide as a hydrophobe,
but inspection of protein–ligand crystal structures (for
example, using the IsoStar system [24]) shows that this
group tends to form hydrophobic interactions perpendicular
to the amide plane, although interactions in the plane are
invariably hydrogen bonds. Non-directional hydrophobes
are groups that are equally hydrophobic in all directions,
such as alkyl chains. Hydrophobes are represented by a
ﬁtting point at the centroid. Optionally, two further ﬁtting
points may be used for directional hydrophobes, placed on
the normal to the least-squares mean plane, one on each
side, at 1 A ˚ from the centroid.
The algorithm for deﬁning hydrophobic features is
similar to that used by others [25]. All rings of size B7 are
classed as hydrophobes (directional if at least three of the
ring atoms are delocalisable, otherwise non-directional).
Groups such as t-butyl and –CF3 are considered non-
directional hydrophobes. Amide, C=C, C=N and N=N
linkages are classed as directional hydrophobes. Other
hydrophobic portions of the molecule (acyclic chains, rings
of size[7) are divided into segments of up to four atoms,
each segment constituting a separate non-directional
hydrophobe. Segments of only three or two atoms are cho-
sen if it leads to more uniform placement of ﬁtting points.
All other feature types are customisable, being deﬁned
by SMARTS (Smiles arbitrary target speciﬁcation) strings
[26]. Any number of feature types may be deﬁned, such as
donors, acceptors, metal coordinators, and positive and
negative centres (in this work, we have only used donors
and acceptors, the latter serving as a surrogate for metal
coordinators). It is necessary to provide a list of SMARTS
strings deﬁning the substructures that belong to each feature
type. SMARTS strings deﬁning donors or acceptors must be
accompanied by two additional data items. One deﬁnes the
strength of the hydrogen bonds formed by the group, cate-
gorised as strong (only used for ionised groups), medium, or
weak (thiourea sulfur acceptors and thiol and C–H donors).
The second data item speciﬁes the preferred geometry of the
hydrogen bonding group. For example, two-coordinate sp
2
nitrogen is deﬁned as a trigonal acceptor (preferentially
hydrogen bonds along its sp
2 lone-pair direction).
CH groups are only classiﬁed as donors if they are in
particularly electron withdrawing environments (for
example, the 2 position of pyrimidine). Phenyl CH groups
are not considered donors. This can make it difﬁcult for the
algorithm to reproduce certain unusual overlays. In Factor
Xa complexes, for instance, Asp189 often forms strong
hydrogen bonds to ligand groups such as amidinium, but it
can also interact with phenyl CH groups (for example, see
PDB complexes 1lpz and 1iqm). The algorithm, however,
will tend not to overlay amidinium NH on phenyl CH.
The location of donor and acceptor ﬁtting points is
customisable but in practice we always place them on the
donor and acceptor atoms rather than on hydrogen and
lone-pair positions, or at the inferred positions of the
complementary hydrogen-bonding atoms on the protein.
Our choice may make it more difﬁcult to ﬁnd overlays in
which two ligand atoms can hydrogen bond to the same
protein atom even though they are not close to each other
in the overlay (for example, because they donate to dif-
ferent lone pairs of the same protein carbonyl oxygen).
However, this situation occurs rather infrequently (based
on an analysis of our test-set complexes) and ﬁtting points
at hydrogen, lone pair or inferred protein-atom positions
make the search space larger (for example, may require
hydrogen-atom torsions to be varied). Also, points lying
outside the molecular envelope (that is, at inferred protein-
atom positions) tend to have unduly large leverage during
overlay generation. Atoms that are both donors and
acceptors (notably hydroxyl oxygens) have both a donor
and an acceptor point placed on them.
It is possible to exclude particular atoms from feature
assignment. For example, the hydrogen-bonding atoms of a
ligand solubilising group could be excluded, meaning that
no donor or acceptor ﬁtting points will be placed on them.
Conversely, special feature types can be deﬁned to contain
sets of hand-picked atoms, rather than atoms matching
SMARTS strings.
Scoring functions
Up to ﬁve scoring functions are used to quantify overlay
quality.
Volume score
This is the union volume of all ligands, V, calculated by
placing a grid over the overlay and counting the points
within the overlay envelope. Small V scores are considered
desirable, since ligands need to bind in a cavity of limited
size. A grid size of 0.5 A ˚ is used by default. Tests on
neprilysin ligand overlays showed that volumes calculated
with this grid size may be in error by up to about 0.5 %,
which is adequate for our purposes.
Hydrogen bond score
Leader-style cluster analysis [27, 28] is used to ﬁnd clusters
of donor and acceptor atoms, each cluster containing only
donors or only acceptors, with no more than one atom from
any given ligand. A cluster need not include an atom from
every ligand. The algorithm works by setting up a ‘‘nearest
neighbour list’’ (NNL) for each donor and acceptor (X) in
the overlay. For a given X, the NNL contains X itself and
the closest donor (or acceptor) to X in each of the other
ligands, provided that it is within 1.5 A ˚ of X. NNLs
J Comput Aided Mol Des (2012) 26:451–472 453
123therefore vary in length; for example, if a given X is[1.5 A ˚
away from all donors (or acceptors) in all other ligands, its
NNL will only contain X itself. The longest NNL is chosen
as the ﬁrst cluster. All members of this cluster are then
removed from the remaining NNLs. The longest of the
remaining NNLs is chosen as the second cluster, and so on
(if NNLs tie on length, the one with the smaller mean square
distance between its members is chosen).
The best consensus hydrogen-bonding direction for the
atoms in each cluster is then determined. Consider, for
example, an acceptor cluster containing phosphate oxygen,
carbonyl oxygen and nitrile nitrogen. For each acceptor,
‘‘virtual points’’ are placed to represent the positions at
whichthecomplementaryproteindonormightlie.Theseare
evenly spaced around the base of a cone for phosphate
oxygen; in the sp
2 lone-pair directions and at intermediate
positions for carbonyl oxygen; and on the sp axis for nitrile
nitrogen. The largest cluster of virtual points is found, using
the same clustering method as above. This represents the
best consensus direction for hydrogen bonding (Fig. 1). The
size of the largest virtual-point cluster might be less than
the size of the parent cluster of donor or acceptor atoms,
indicating that they cannot all hydrogen-bond in the same
direction. Steric accessibility is assessed by placing points
on the line between the centroid of the donor or acceptor
atoms and the centroid of the chosen virtual-point cluster.
Each point is examined to determine whether it falls within
the hydrophobic envelope of the overlay and an occlusion
factor, X, is calculated which varies from 1 if there is a clear
line of sight to 0.1 if the points are highly occluded.
In the protein–ligand structures of our test set, there is
no example of a protein atom forming hydrogen bonds to a
strong donor or acceptor on one ligand but a weak donor or
acceptor on another (using our deﬁnitions of strong and
weak). Hydrogen bonding is always to ligand groups of the
same strength or (less commonly) to a mixture of strong
and medium, or medium and weak. To reﬂect this, the
similarity of the donor or acceptor atoms in each cluster is
estimated by a factor S = (m/n)
2, where n is the actual
number of atoms in the cluster and m is an ‘‘effective’’
number, set equal to n if all atoms in the cluster have the
same strength, but to lower values otherwise.
The hydrogen-bond score (larger values better) is:
HB ¼ R SpXp A2
pfðapÞþV2
pgðvpÞ
hi no
ð1Þ
Summationisoverthedonorandacceptor atomclusters(ifa
set of hydroxyl groups contributes to both donor and
acceptor clusters, the contribution of the less well-scoring
clusterisignored).SpandXparethesimilarityandocclusion
factorsforclusterp;Apisthenumberofatomsinthecluster;
Vp is the number of virtual points in the largest virtual-point
cluster(intheeventofatie,thescoreiscalculatedforeachin
turn and the highest value taken); ap is the mean square
distance of the atoms from their centroid; vp is the corre-
sponding quantity for the virtual-points. f(ap) is a weighting
function which falls linearly from 1.0 to 0.3 as ap increases
from 0.15 to 0.75 A ˚ 2, taking constant values of 1.0 and 0.3,
respectively, below and above these distances; g(vp)i s
similar but falls between 1.0 and 0.3 as vp varies from 0.5 to
1.5 A ˚ 2. The effect is to reward tight clusters.
Hydrophobic score
Leader cluster analysis (see above) is used to ﬁnd clusters
of directional hydrophobes. A cluster may contain no more
than one hydrophobe from each ligand and need not con-
tain a hydrophobe from every ligand. Inter-planar angles
are calculated between all pairs of hydrophobes in each
cluster. The score (larger values better) is:
HY ¼ R N2
p½fðnpÞþgðcpÞ 
no
ð2Þ
Summation is over the clusters. Np is the number of
hydrophobes in cluster p; np is the mean-square distance of
the centroids of the hydrophobes in the cluster from the
mean position of these centroids; cp is the average cosine of
the inter-planar angles. f(np) is a weighting function which
falls linearly from 1.0 to 0.0 as np increases from 0.0 to
1.25 A ˚ 2, remaining constant at zero thereafter, g(cp)i s
similar in form but falls from 2.0 to 0.0 as cp decreases
from 1.0 to 0.8. Hence, more weight is placed on the hy-
drophobes being coplanar than on their centroids being
coincident.
Fig. 1 Example overlay of nitrile, carbonyl and phosphate acceptors.
Each acceptor is shown with virtual points representing possible
positions of the protein donor (magenta: nitrile; green: carbonyl;
brown: phosphate). A direction in which all three acceptors can
hydrogen bond is indicated by the cluster of virtual points, one from
each acceptor, at the top left of the ﬁgure
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This is the sum of the strain energies of the overlaid ligands,
E, calculated from the torsional and van der Waals (vdw)
terms of the Tripos force ﬁeld [29]. Only repulsive atom–
atom interactions are included in the vdw sum, to avoid
attractive interactions artiﬁcially favouring folded confor-
mations. As bond angles are not allowed to relax, all vdw
radii are reduced to 0.85 times their published values; a
similar approach has been used previously by others [30].
Also, the worst atom–atom clash is ignored provided its
energy is \150 kcal/mol, making the function more for-
giving when a conformation has a single bad atom–atom
clash that could probably be relieved if bond angles were
allowed to vary.
Customised-feature score
This is employed when the user has deﬁned customised
features (feature types other than hydrophobes, donors or
acceptors). Clusters of customised-feature centroids are
found, each cluster containing only one type of customised
feature and no more than one centroid from each ligand.
The score (larger values better) is:
CF ¼ R N2
pfðnpÞ
no
ð3Þ
Summation is over the clusters. Np is the number of
customised-feature centroids in cluster p; np is the mean-
square distance between the customised-feature centroids
and their overall centroid; f(np) is a weighting function
which falls linearly from 1.0 to 0.0 as np increases from 0.0
to 1.25 A ˚ 2, remaining constant at zero thereafter.
Chromosome structure
At some stages of the algorithm,it is convenientto represent
overlays not by their atomic coordinates but as a compact
representation which we call a chromosome. We use this
namebecause,amongstotheruses,chromosomesareusedto
represent solutions in a MOGA during overlay multiplica-
tion. However, they are also used for other purposes unre-
lated to genetic algorithms: they provide a concise way of
storing the large numbers of putative solutions produced by
the overlay-generation stage of the algorithm; and they are
used for efﬁcient persistent storage of solutions.
A chromosome must fully deﬁne the conformation,
position and orientation of each ligand. A ligand confor-
mation is deﬁned by: (a) a conformer index, which refers to
one of the low-energy conformations supplied by the user;
(b) a set of torsion-angle values for the acyclic rotatable
bonds. (A ﬁle of SMARTS strings is used to indicate which
types ofacyclicbonds are to be considered rotatableand can
also be used to set allowed torsion-angle ranges. For
example, we do not rotate methyl groups, and constrain
esters to lie within 5  of the trans planar geometry.) The
required conformation is generated by setting the molecular
geometry to that of the speciﬁed conformer and then driving
the rotatable bonds to their required torsion settings. The
chromosome may contain no torsion data, in which case the
indicated conformer is used directly. When torsion angles
are supplied, it is still necessary to specify a conformer
index in case the ligand contains a ﬂexible ring or invertible
nitrogen, in which case different conformers in the input ﬁle
might have different ring or nitrogen geometries.
The positions and orientations of the ligands are deﬁned
by a mapping table which speciﬁes a matching of ﬁtting
points. For example, for a three-ligand overlay it might
look like:
ligand A: 1 7 9; ligand B: 4 6 10; ligand C: 2 4 6
This means that ligand B is to be overlaid on ligand A
(once they have been set to their speciﬁed conformations)
by least-squares superposition of its ﬁtting points 4, 6, 10
on 1, 7, 9, respectively, of ligand A. Ligand C is overlaid
by least-squares superposition of its ﬁtting points 2, 4, 6 on
points a, b, c, where a is the centroid of ﬁtting point 1
(ligand A) and ﬁtting point 4 (ligand B), and so on. The
table may contain more than three columns and missing
values are allowed. If there are fewer than three columns in
the table with no missing values, the algorithm will search
for an order in which the ligands can be overlaid. If none
can be found, the chromosome is invalid.
The chromosome may also contain three translations
and three Euler angles per ligand. If so, the ligand positions
are further modiﬁed after the mapping-table superpositions
by rigid-body rotations about the x, y and z directions,
followed by translations. This was implemented to allow
ligands to rotate and translate freely during overlay
reﬁnement and multiplication.
Overlay generation
This involves three stages: triplet counting, ﬁngerprint
calculation, and ﬁngerprint searching. For simplicity, the
procedure will be described assuming that only donor,
acceptor and hydrophobe feature types are in use, but
extension to more feature types is straightforward.
Triplet counting
A triplet is deﬁned as three ﬁtting points from the same
conformation of a ligand. Triplets can be classiﬁed into
types, deﬁned by: (a) the nature of the features that the
three ﬁtting points represent (donors, acceptors or hydro-
phobes); (b) the inter-point distances. By using a set of
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can be assigned uniquely to one bin, so each triplet can be
assigned uniquely to one triplet type. The ﬁrst step is to
ﬁnd the triplet types that occur most often in the ligand
conformations that the user has supplied. All triplets are
enumerated and typed. Let Li be the number of ligands in
which at least one triplet of type i occurs in at least one
conformation. Let Pij be the proportion of conformations of
ligand j that contain at least one triplet of type i. Let Pi be
the average of the Pij over all ligands. Triplet types are
sorted in descending order of Li and, in the event of ties, in
descending order of Pi. The position of a triplet type in the
sorted list is its rank, starting at 1 for the most common. Let
M be the rank of the lowest-ranked triplet type that occurs
in all ligands. Overlay generation, as described below,
proceeds by iterating over the triplet types from rank 1 to
N, where N is the lesser of M and a user-deﬁned value (set
to 25 for the validation described below). In each iteration
step, overlays are generated by superposition of triplets of
the type under consideration in that step. Overlays from all
iteration steps are pooled and taken forward to the ﬁltering
stage.
All the results discussed below were obtained using
triplets derived solely from ﬁtting points placed on
acceptors, donors and the centroids of hydrophobic groups.
However, we have found that it can sometimes be advan-
tageous to also allow triplets containing ﬁtting points on
the normals to directional hydrophobes.
The use of distance bins may lead to a problem. Two
triplets that are identical in all respects except for a small
discrepancy in one of the distances will be assigned to
different triplet types if the slightly discrepant distances fall
either side of a bin boundary. We therefore run the entire
overlay generation procedure twice, using different bin
deﬁnitions. The overlays from the two runs are pooled
before ﬁltering. By default, the ﬁrst set of bins is: 0.5–3.0,
3.0–5.0, 5.0–7.0, 7.0–9.0, 9.0–11.0, 11.0–13.0 A ˚. The
second is: 0.5–3.5, 3.5–6.0, 6.0–8.5, 8.5–11.5, 11.5–
13.5 A ˚. Triplets are ignored if they involve a distance
below the lowest bin boundary, or above the highest.
Fingerprint calculation
For a given iteration step, let the triplet type under consid-
eration be called the base triplet type, and let a triplet
belongingtothattypebeabasetriplet.Theaimistoperform
a multiple alignment of all ligand conformations containing
a base triplet so that, for each such conformation, the base
triplet is placed in a standard position and orientation. The
positionsinCartesianspaceofallﬁttingpointsofthealigned
conformations (excluding the base-triplet ﬁtting points) are
mapped onto a 3D grid which is converted into a ﬁngerprint
(Fig. 2). The ﬁngerprint allows rapid searching for
combinations of ligand conformers (one per ligand) whose
ﬁtting points occupy similar positions in space.
Thealgorithmloopsoverallconformationsofallligands.
Foreachconformation,onlytheﬁttingpointsareconsidered,
not the atoms. If the conformation does not contain a base
triplet it is rejected. If it does, the points of that triplet are
numbered 1, 2 and 3 by a simple canonicalisation algorithm.
(Acceptor points are assigned lower numbers than donor
points,anddonorslowerthanhydrophobes.Ifallthreepoints
have the same type,numbering is such that the bins in which
the inter-point distances lie are in the order 2–3 B
1–3 B 1–2. When points 1 and 2, but not 3, have the same
type,theruleis2–3 B 1–3;when2and3,butnot1,havethe
same type, then 1–3 B 1–2.) The rotation/translation trans-
formation is calculated that places the triplet centroid on the
origin,point1onthe?xaxis,andpoint2inthexyplanewith
y C 0. This transformation is applied to all ﬁtting points of
the conformation. The resulting ﬁtting-point positions are
stored. If the base triplet is degenerate, so that there is no
unique canonicalised order, all valid orderings are used in
turn, a separate set of ﬁtting-point positions being generated
for each. If the conformation contains more than one base
triplet, the process is repeated for each in turn.
A 3D grid is constructed, large enough to enclose all the
ﬁtting-point positions generated by the above procedure.
By default, a grid resolution of 1.5 A ˚ is used. Let the
number of points in the grid be G. Each set of ﬁtting points,
corresponding to a particular ligand conformation aligned
with a base triplet in the standard orientation, is converted
to a ﬁngerprint as follows. A bit string of length 3G is
created. The ﬁrst segment of G bits will capture donor
ﬁtting-point positions, each bit corresponding to one of the
grid points. The other two segments will capture acceptor
and hydrophobe-centroid ﬁtting-point positions. All bits
are initialised to 0. Each ﬁtting point in the ligand con-
formation (except those of the base triplet) is mapped to its
nearest grid point and to the six adjacent points in the ±x,
±y and ±z directions. Depending on the type of feature
that the ﬁtting point represents, the bits corresponding to
these seven grid points in the donor, acceptor or hydro-
phobe segment of the bit string are set to 1. The purpose of
setting seven rather than one bit is to smear out the ﬁtting
point and hence make the algorithm more forgiving.
However, this may be unnecessary as results appear
equally good if smearing is switched off (that is, just the bit
corresponding to the nearest grid point is switched on).
When allaligned conformationshavebeen processed,the
result is a ﬁngerprint table (we call it an alignment ﬁnger-
print), each row corresponding to an aligned ligand confor-
mation, each column to a particular grid point and feature
type.Emptycolumnsareeliminated.Eachrowofthetableis
quite similar to a Bloom ﬁngerprint, as used in the Pharmer
program [31], but the rows are not hashed, ﬁtting points can
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macophore elucidation rather than the screening of phar-
macophore searches.
Fingerprint searching
The alignment ﬁngerprint is searched for combinations of
rows (one row from each ligand) that have high concor-
dance. This is equivalent to searching for ligand confor-
mations (one per ligand) that, when overlaid by
superimposing the base triplet ﬁtting points, have other
ﬁtting points close together. Searching for good row
combinations is the rate-limiting step of overlay genera-
tion. Each trial combination of rows is scored by:
B ¼ wA   O ð4Þ
A is the number of bits set on in the bit string obtained
by logically ANDing the trial set of rows; O is the
corresponding quantity for the bit string produced by
logical OR; w is an integral weight (default w = 2).
A bit value of 1 in the AND string is suggestive of a full
pharmacophorepoint, since the alignedligandconformations
correspondingtotheANDedrowsmustallhavethesametype
of ﬁtting point mapped to the same grid point. Thus, large
valuesofA are favourable. Conversely, small valuesofO are
desired, since the more ‘‘column sharing’’ there is (two or
more of the selected rows having ‘‘on’’ bits in the same col-
umn), the higher the concordance of the selected rows. O is
sensitive both to full and partial pharmacophore points. The
larger the weight w, the greater the premium placed on full
points.
Finding good row combinations is achieved with a
greedy algorithm which involves n steps, where n is the
number of ligands. In the ﬁrst step, a starting row is chosen.
Selection is biased towards rows containing a large number
of ‘‘on’’ bits in highly occupied columns. In the second
step, one of the ligands is chosen at random, subject to the
constraint that it cannot be the ligand to which the row
selected at step 1 belongs. Every row belonging to the
second ligand is ANDed and ORed with the starting row,
and the one producing the best B value accepted (if there is
a tie, one of the tied rows is selected at random). The
remaining steps proceed in similar fashion. At each step,
rows corresponding to the new ligand are combined with
Fig. 2 Simpliﬁed example of ﬁngerprint algorithm. Two molecules
are represented as collections of ﬁtting points, shown as circles for
one molecule, triangles for the other. The ﬁtting points represent two
types of chemical features, red and green. The molecules contain
approximately congruent triangles of ﬁtting points (outlined in black),
the ‘‘core triplets’’. The ﬁtting points of each molecule are oriented so
that their core triplets are approximately superimposed, and a grid
placed over the resulting ﬁtting-point assembly (bottom left). Each
ﬁtting point, except those of the core triplets, is mapped to the nearest
grid point. For example, the red triangle at the top is mapped to the
grid point shown by the purple arrow. A bit string is created for each
molecule to represent grid-point occupancy, the ﬁrst (last) 16 bits
capturing occupancy by red (green) features. For example, the second
bit for the triangle molecule is set to 1 because the second grid point
(counting in rows starting at top left) is occupied by a red ﬁtting point.
There are two positions in which both bit strings have on bits,
revealing the close proximity of the circled ﬁtting points
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already accepted.
Typically, we generate 200 solutions (row combina-
tions) from each ﬁngerprint. This number is under the
user’s control. Each run of the greedy algorithm produces
one solution. Thus, if P solutions are required from a ﬁn-
gerprint, they are generated by using P different starting
rows, unless P exceeds the number of rows in the ﬁnger-
print. In this case, the rows are iterated over again, but
using different ligand ordering during the greedy algo-
rithm. The larger P, the more thorough the search. All the
solutions from all ﬁngerprints are pooled, giving 10,000
solutions in total when 25 ﬁngerprints are used for each of
two distance-bin deﬁnitions. The total number will be less
than this if fewer than 25 ﬁngerprints can be constructed
for either set of distance bins; this will occur if fewer than
25 triplet types occur in all of the ligands. The solutions are
stored as chromosomes. In each chromosome, the mapping
table contains the indices of the ﬁtting points comprising
the base triplets of the rows in the solution, and the con-
former indices reﬂect the ligand conformations from which
the rows were constructed. Each chromosome can be used
to construct the corresponding molecular overlay.
Stepwise approach
A limitation of the method is that overlays can only be
generated from base triplets that occur in at least one con-
formationofeveryligand.Ifthereisnosuchbasetriplet,one
possible remedy is to create overlays in stepwise fashion.
The overlay generation is ﬁrst run on a subset of ligands
which do share a common base triplet. After ﬁltering, this
will result in several overlays of the subset of ligands. The
program can treat these as ‘‘conformations’’ of a ‘‘super-
molecule’’, for each of which ﬁtting points are placed to
representthefeaturesofalltheligandsintheoverlay.Where
ﬁtting points of the same type from different ligands are
close together, they are merged into a single, average point.
This is done by leader cluster analysis (see above). By
default, points separated by[1.5 A ˚ will not be placed in the
same cluster and therefore will not be merged. Because the
supermolecule has more ﬁtting points than any of the indi-
vidual ligands from which it is comprised, there is an
increased chance of ﬁnding common base triplets between it
andthe remainingligands.Overlaysofthe complete set may
therefore be built up by a succession of steps. Users must
specify the number and nature of the steps in a stepwise
overlay generation. A step can involve overlaying super-
molecules on other supermolecules. For example, when
overlaying ligands L1, L2, L3 and L4, a typical step speci-
ﬁcation might be: L1 on L2 to give supermolecules
(L1 ? L2); L3 on L4 to give supermolecules (L3 ? L4);
(L1 ? L2) on (L3 ? L4) to give the ﬁnal overlays. A step
can involve both supermolecules and ordinary molecules;
for example: L1 on L2 to give (L1 ? L2); (L1 ? L2) on L3
and L4 to give the ﬁnal overlays.
Constraints
The algorithm can be used to generate constrained overlays.
For example, suppose all the ligands contain a quaternary
nitrogen atom and the user is only interested in overlays in
which these atoms are superimposed. An artiﬁcial ‘‘con-
straint’’ feature type is introduced, to which only the qua-
ternary nitrogen atoms belong, a ﬁtting point being placed on
each. During triplet enumeration, triplets which do not con-
tain one of these ﬁtting points are rejected. The ensuing
ﬁngerprint algorithm is therefore constrained to produce only
solutions which superimpose the quaternary nitrogen atoms.
Overlay ﬁltering
Filtering aims to select a diverse subset of the best of the
generated overlays. The procedure begins by scoring the
overlays, using some or all of the objective functions
described earlier, either separately or as a weighted linear
combination. By default, we use volume, hydrogen bond
and hydrophobic scores, but not energy, as all ligand
conformations in the generated overlays will have been
taken directly from the conformers supplied by the user.
The objective functions are computed separately and con-
verted to a single number by Fonseca-Fleming Pareto
ranking [32]. Overlays whose Pareto rank exceeds a
threshold (set by default to 5) are rejected.
When Pareto ranking, we usually set score constraints.
In unconstrained Pareto ranking, one solution will be
deemed to dominate another if, and only if, it scores better
on at least one objective and does not score worse on any
objective. When a score constraint is applied (for example,
V\900), an extra rule is invoked: for any pair of solu-
tions, if one breaks a constraint (for example, V = 901)
and the other does not, the solution breaking the constraint
is deemed to be dominated by the other. Score constraints
can be speciﬁed in absolute or percentile terms. By default,
we use the latter, requiring that an overlay must be in the
best 30 % of volume scores and the best 30 % of hydrogen-
bond scores to avoid breaking a constraint.
Typically, we limit the ﬁnal number of solutions after
ﬁltering to B20. Thus, if application of the Pareto rank
threshold leaves too many solutions, they are further
reduced in number as follows. They are ordered on their
Borda tallies (the sum of the ranks of the individual
objective scores [33]). The highest ranking solution (best
on Borda tally) is chosen to be part of the ﬁnal solution set.
Solutions similar to this one are rejected. The best solution
of those that remain is chosen, similar solutions rejected,
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chosen or the solutions are exhausted. Similarity is mea-
sured by the consensus coefﬁcient described later; solutions
are rejected if their dissimilarity from any overlay already
accepted is\0.05.
Overlay reﬁnement
This has the purpose of improving an already good overlay
fromtheprecedingstepsbybringingapproximatelyoverlaid
groups into tighter alignment. Reﬁnement can be achieved
by simulated annealing, randomly changing one ligand tor-
sionvalue,orapplyingasmallrandomrigid-bodytranslation
orrotationtooneligand,ineachstep.Changedtorsionvalues
must respect any torsion-angle constraints set by the user.
Thefollowingcostfunctionusuallygivesacceptableresults:
F ¼ HB   0:5V þ HY   0:3E ð5Þ
The initial annealing temperature is typically set to a low
value, because the aim is to achieve minor improvements
rather than perform a wide exploration of overlay space.
Annealing is usually successful at producing well-reﬁned
solutions, but it is slow. We have recently developed a much
faster method using gradient-based optimisation, full details
of which will be published in a subsequent paper.
Overlay multiplication
This aims to take a good overlay and investigate whether
other alignments exist with the same mapping of features
but different ligand conformations (Fig. 3). This is often
possible if the ligands are ﬂexible, and of practical concern
if the aim is to produce a pharmacophore query for virtual
screening. Ideally, all possible solutions should be found at
the overlay generation stage, but only a limited number of
solutions will normally be requested, and the diversity
algorithm used during ﬁltering may bias selection towards
overlays expressing different feature mappings.
The multiplication procedure is related to the algorithm
described in our earlier publications [17–19] .T h eﬁ r s ts t e pi s
to construct a chromosome mapping table that reﬂects all the
full and partial pharmacophore points in the starting overlay.
A population of 150 chromosomes is set up, each containing
this mapping table but with randomised torsion-angle values.
The population is subjected to MOGA optimisation. 150
childrenareproducedineachgenerationbytorsionmutations,
torsioncrossovers,orsmallmutationstotherigid-bodyligand
rotation or translation data. Each mutation is restricted to a
singletorsionvalueortotherigid-bodytranslationorrotation
data of a single ligand. In each torsion crossover, the swap is
restricted totorsion angles involving a singleligand. Mutated
torsion values must respect any torsion-angle constraints set
by the user. Parents are chosen by tournament selection.
At each generation, parent and child populations are
merged and Pareto ranked, using the objective functions V,
HB, HY and E. Up to 150 chromosomes from the merged
population are accepted for the next generation. Selection
is based on Pareto ranks, with niching to promote geo-
metric diversity. Chromosomes are placed in the same
niche if the dissimilarity of the overlays for which they
code is less than a set value. Once a niche is full, no further
chromosomes that would belong to that niche can be
accepted. For speed, dissimilarity is measured not by the
coefﬁcients described below but by the following crude
technique. A subset of atoms is chosen, including one from
(or very near to) every feature of every ligand. For each
overlay, the matrix of squared distances between the cho-
sen atoms is calculated. The dissimilarity of an overlay pair
is determined by the mean absolute difference between
corresponding elements of their squared distance matrices.
Solution analysis
The following methods were programmed to aid compar-
ison of the overlays produced for a set of ligands.
Overlay dissimilarity coefﬁcients: introduction
Two questions are relevant when comparing a pair of over-
lays of the same ligands. First, are the same ligand groups
matched (that is, how different are the pharmacophores in
Fig. 3 Two overlays of dihydrofolate reductase ligands with identi-
cal feature mappings but different ligand conformations (and
therefore leading to different pharmacophore queries)
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contain, and the individual ligand ﬁtting points that con-
tribute to them)? Second, are the overlays similar geomet-
rically? We therefore use three dissimilarity measures, one
pharmacophore based, one based on geometry, and the third
a consensus measure.
Pharmacophore dissimilarity coefﬁcient
The pharmacophore present in each of the overlays (A, B)
to be compared is identiﬁed by cluster analysis of the
ligand ﬁtting points. All pairs of pharmacophore points,
one from A and one from B, that are of the same type (all
donor pairs, all acceptor pairs, and so on) are examined.
For a given pair, PA and PB, let NA be the number of ligand
ﬁtting points in PA,N B be the number in PB, and NAB be
the number that are in both PA and PB. The similarity of the
pair is computed by the Tanimoto metric T = NAB/
(NA ? NB - NAB). The weight of the pair is deﬁned as
w = [(NA ? NB)/2]
2.
Pharmacophore points in A are then matched with those
in B, by ﬁrst matching the pair with the highest Tanimoto
coefﬁcient, then the pair with the next highest (excluding
any pair involving a pharmacophore point that has already
been matched), and so on. Some pharmacophore points
may be left unmatched. For these, the quantity U = RNi
2 is
calculated, where summation is over the unmatched phar-
macophore points and Ni is the number of ligand ﬁtting
points in the ith unmatched point. The pharmacophore
dissimilarity coefﬁcient, Dp, is calculated as
Dp ¼ 1  ð RwiTiÞ=ðU þ RwiÞð 6Þ
the summations being over the matched pairs.
Geometric dissimilarity coefﬁcient
The geometric dissimilarity of overlays A and B is quan-
tiﬁed by least-squares ﬁtting a selection of atoms in A,
chosen to include one atom from (or very near to) every
feature of every ligand, onto the corresponding atoms in B.
To allow for local topological symmetry, a two-step pro-
cedure is used. In step 1, the selected atoms of each ligand
in A are least-squares ﬁtted onto the selected atoms of the
corresponding ligand in B, using all possible ways of
matching the atoms (given that there may be many ways of
matching the ligand graph onto itself). For each ligand, the
atom pairing giving the lowest root mean square deviation
(rmsd) is stored. In step 2, A is least-squared ﬁtted onto B,
using the atom pairings stored from step 1. The interatomic
distance of each matched atom pair in the superposition of
A and B is converted to a normalised quantity q by the
transformation:
q ¼ 0i f d \0:5 ˚ A; q ¼ð d   0:5Þ=ð3:5   0:5Þ
if 0:5 d 3:5 ˚ A; q ¼ 1i f d [3:5 ˚ A
The dissimilarity coefﬁcient, DG, is the average of the q
values.
Consensus dissimilarity coefﬁcient
The consensus dissimilarity, DC,i sH(DPDG).
Superposition of overlays
Any two overlays can be superimposed automatically to
aid their comparison. Superposition is achieved either by
least-squares ﬁtting of atoms or of pharmacophores (using
pharmacophore-point pairings derived from calculating the
DP coefﬁcient). If the latter is used, the consensus phar-
macophore of the two solutions is also calculated and
displayed.
Mapping of overlays
Multidimensional scaling (performed with the SMACOF
algorithm [34]) is used to produces 2D or 3D plots of the
ﬁnal set of overlays, the intention being that similar over-
lays should lie close together on the plot [35]. Three sep-
arate plots are calculated, based on each of the dissimilarity
coefﬁcients described above. Plots can be coloured on any
of the objective scores. The plots can be very revealing. For
example, Fig. 4 shows that solutions fall into two main
clusters, with two gross outliers. However, overlays are
complex objects and variations between them can be rep-
resented only approximately in low dimensional space.
Thus, while useful, the plots should not be over-interpreted.
Fig. 4 Plot of overlays of cycle checkpoint kinase ligands, revealing
that the overlays fall into two distinct clusters, with two outliers (the
horizontal and vertical axes represent the ﬁrst and second dimensions,
respectively, from the multidimensional scaling calculation)
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Parameters used in the hydrogen bond and hydrophobic
scores were chosen so that the relative contributions to these
scores of the various clusters of donors, acceptors and hy-
drophobes in the true overlays of the test set seemed rea-
sonable, in our subjective judgement. The extent to which
vdw radii were reduced for calculation of the energy score,
and the strategy of ignoring the worst contact provided it
was less repulsive than 150 kcal/mol, were chosen to give
good discrimination between the calculated energies of
(a) OMEGA-generated and (b) randomly-generated con-
formations of the test-set ligands. The premium placed on
full pharmacophore points when searching alignment ﬁn-
gerprints (w in Eq. 4), the number of ﬁngerprints used, the
number of overlays generated per ﬁngerprint, and the ﬁlter
thresholds and score constraints, were selected by manual
experimentation on two of the ten sets of ligands used in the
validation (neprilysin and dihydrofolate reductase ligands).
Validation
Test data
The program was tested on ten sets of protein–ligand
complexes from the PDB (Table 1), and on some subsets
thereof (Table 2). All complexes are members of the Astex
Non-Native Set, which was compiled from well-reﬁned
structures with a bias towards therapeutically relevant
proteins [36]. The complexes in each set were superimposed
by least-squares ﬁtting the binding-site atoms in Relibase?
[37], hence producing the true, crystallographically-
observed overlay. Each complex was inspected to establish
probable ligand protonation states and identify protein–
ligand interactions. This enabled the true pharmacophore
points to be determined (clusters of atoms or groups that
form common interactions with the protein) and distin-
guished from incidental clusters of donors, acceptors and
hydrophobes (for example, clusters of acceptors or donors
that interact only with solvent).
Ligand models were created with CORINA [38] with
addition of required hydrogen atoms. Six sets of conformers
were generated for all ligands. Three (RAW5000,
RAW1000 and RAW200) were produced using the raw
CORINA-generated molecules as input, with the maximum
number of conformers per ligand set to 5,000, 1,000 and
200, respectively. The OMEGA rms and ewindow param-
eters were set to 0.5 A ˚ and 10 kcal/mol, respectively, and
the –fromCT ﬂag set to false; default values were used for
other parameters. The remaining conformer sets (OPT5000,
OPT1000 and OPT200) were generated in similar fashion
except that the CORINA models were subjected to geom-
etry optimisation with the SZYBKI molecular mechanics
program [39] before input to OMEGA. OMEGA changed
the bond types of a small number of chemical groupings (in
particular, removing the formal charge on some aromatic
nitrogens by making the ring non-aromatic) but we felt the
error was sufﬁciently unimportant that it could be ignored (a
conservative decision, since sub-optimum bond types are
likely to worsen rather than improve validation results). A
table is included in the Supporting Information giving, for
each ligand, the non-hydrogen atom rmsd between the
binding conformation and the closest approximation to that
conformation in each conformer set. In general, these are
satisfactorily small.
Table 1 Test sets Protein Number of
complexes
PDB codes
Protein kinase 5 (PK5) 2 1v0o, 1v0p
Fatty acid binding protein (FABP) 3 1tou, 1tow, 2hnx
Neprilysin (NEP) 4 1dmt, 1r1h, 1r1j, 1y8j
Dihydrofolate reductase (DHFR) 6 1drf, 1hfr, 1mvt, 1pd9, 1s3v, 2dhf
Checkpoint kinase (Chk1) 16 1nvq, 1nvr, 1nvs, 1zlt, 1zys, 2br1, 2brb, 2brg,
2brh, 2brm, 2bro, 2c3l, 2cgu, 2cgw, 2cgx, 2hog
Neuraminidase (NEU) 11 1a4g, 1a4q, 1b9s, 1b9t, 1b9v, 1inf, 1inv, 1ivb,
1nsc, 1nsd, 1vcj
Carbonic anhydrase (CA) 13 1bn3, 1bn4, 1bnq, 1cim, 1eou, 1if7, 1oq5, 1xpz,
1zgf, 1zh9, 2eu3, 2hoc, 2nng
Adenosine deaminase (ADA) 11 1krm, 1ndv, 1ndw, 1ndy, 1o5r, 1qxl, 1uml,
1v7a, 1v79, 1wxy, 2e1w
Heat shock protein 90 (HSP) 10 1byq, 1uy8, 1yc1, 1yc4, 1yet, 2bsm,
2byi, 2bz5, 2cct, 2uwd
Acetylcholinesterase (AChE) 11 1dx6, 1e66, 1eve, 1gpk, 1gpn, 1h23, 1w4l,
1zgb, 2ack, 2c5g, 2ckm
J Comput Aided Mol Des (2012) 26:451–472 461
123Success criteria
Choosing success criteria is not easy. First, it cannot be
assumed that the true overlay is the most plausible way in
which the ligands can be aligned. It is possible that an
incorrect solution may look more convincing and such a
solution should be presented to the user for consideration.
Second, it is more important to correctly predict the feature
mappings than the ligand conformations. An overlay with
correct feature mappings is very useful, even if the ligand
geometries are wrong, because: (a) it indicates which
functional groups are important for binding; (b) the phar-
macophore query it suggests will probably ﬁnd useful hits
(since ﬂexible active molecules in the search database may
be able to adopt the conformations required to match the
query); (c) it can serve as a starting point for overlay
multiplication. Third, the all-atom rmsd from the true
overlay is a poor success measure, since it can be low even
if the prediction has serious faults [15]. We therefore deﬁne
success as generating an overlay with substantially correct
feature mappings (preferably, but not necessarily, in their
correct relative positions) in the small number of highly
ranked solutions that a user is likely to view (we have
assumed users will inspect up to 20).
The pharmacophore points (full and partial) in each true
overlay were manually divided into groups. For example,
those of the NEP ligands (Fig. 5) were divided into: (a) the
acceptor points representing the acidic atoms that coordi-
nate the active-site zinc and hydrogen bond to His711 and
Glu584; (b) the pair of donor and acceptor points repre-
senting amide and imidazo groups that hydrogen bond to
Asn542 and Arg717; (c) the hydrophobic point represent-
ing phenyl and isobutyl groups that interact with Val580,
Trp693 and other nearby residues; (d) the acceptor point
corresponding to carboxylate oxygen atoms that hydrogen
bond to Asn542. Each pharmacophore-point group was
classiﬁed as being of major, moderate or minor importance,
depending on whether it contains full pharmacophore
points, partial points involving several of the ligands, or
partial points involving only a small number of ligands.
Table 3 summarises the pharmacophore-point groups for
the NEP ligands. Analogous tables for other test sets are
available as Supporting Information, together with anno-
tated ligand chemical diagrams.
We then identiﬁed the atoms (donors, acceptors and
dummy atoms at the centroids of hydrophobes) that con-
stituted the pharmacophore points in each group (for
example, the carboxylate oxygens constituting group d of
the NEP ligands). For any given predicted overlay, we
calculated the quantities Ri,i= 1, 2,…, N, where N is the
number of pharmacophore-point groups and Ri is the rmsd
obtained when the atoms constituting the pharmacophore
points of the ith group in the true overlay are least-squares
ﬁtted onto the corresponding atoms in the predicted overlay.
We also calculated Rtotal, the rmsd obtained when all atoms
of the true overlay that were included in any Ri calculation
are least-squares ﬁtted onto the corresponding atoms of the
prediction. If all Ri are small, the predicted overlay has all
the correct pharmacophore points but not necessarily in
their correct relative positions (that is, correct feature
mappings but possibly incorrect ligand conformations). If
both Rtotal and all the Ri are small, the predicted overlay has
correct feature mappings and ligand conformations. In
addition to these objective measures, we also assessed
Table 2 Test subsets
Protein/subset Number of
complexes
PDB codes
ADA/1 10 1ndv, 1ndw, 1ndy, 1o5r, 1qxl, 1uml,
1v7a, 1v79, 1wxy, 2e1w
ADA/2 4 1o5r, 1qxl, 1uml, 1wxy
ADA/3 4 1ndv, 1o5r, 1qxl, 1uml
HSP/1 7 1yc1, 1yc4, 2bsm, 2byi, 2bz5, 2cct,
2uwd
HSP/2 3 1byq, 1uy8, 2cct
AChE/1 9 1dx6, 1e66, 1gpk, 1gpn, 1h23, 1w4l,
1zgb, 2ack, 2ckm
AChE/2 4 1h23, 1w4l, 1zgb, 2ckm
Fig. 5 True overlay of neprilysin ligands showing the pharmaco-
phore-point groups (in ball-and-stick style) referred to in the text
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overlay and manually looking for misplaced ligands.
Results
Up to 20 solutions were produced for each test set,
including the subsets in Table 2. RAW5000 conformers
were used as input and all program parameters were set at
their default values. No overlay reﬁnement or multiplica-
tion was performed unless otherwise stated below. The
solutions in each set were ranked from 1 to 20, based on
their Borda tallies for the V, HB and HY objective func-
tions (see Overlay Filtering). Each solution was charac-
terised by its Ri and Rtotal values and many were manually
inspected. Table 4 summarises the results. The Ri and Rtotal
values (in A ˚) pertain to the solution that appeared to us to
best represent the true overlay. Successive Ri values on
each line correspond to pharmacophore-point groups a, b,
c, etc. in Table 3 and the analogous tables in Supporting
Information, and are separated into those that represent
groups of major, moderate and minor importance. The
number of seriously misplaced ligands (if any) in the
solution is given, together with the solution rank (column
headed ‘‘rank, best’’). The table also shows the rank of the
highest-ranked solution that had substantially correct fea-
ture mappings but not necessarily the correct geometry
(‘‘rank, highest’’). For some sets (listed at the foot of the
table), none of the solutions were considered satisfactory;
Ri and Rtotal are not given in these cases.
Discussion
Discussion is conﬁned to the results from the RAW5000
conformer set, with a brief summary of the effects of using
other conformer sets at the end.
Protein kinase 5
The main problem with this otherwise simple test set is that
both ligands contain acid groups, and we might expect the
algorithm to produce overlays in which these groups are
superimposed.However,theacidgroupsarewidelyseparated
inthetrueoverlay,neitherforminganysigniﬁcantinteractions
withtheprotein.Ideally,theprogramshouldgenerateboththe
correctsolutionandtheobviousbutincorrectalternative.This
isachieved.Onlyninesolutionssurvivetheﬁltering,ofwhich
Table 3 Pharmacophore-point
groups for the neprilysin ligands
a Number of full
pharmacophore points in group
b Number of partial
pharmacophore points in group
Group Description Full
a Partial
b Importance
a Acidic groups (including thiolates) binding Zn,
accepting from E584, H711
1 1 Major
b Amide and imidazo groups donating to N542,
accepting from R717
2 0 Major
c Phenyl and isobutyl groups making hydrophobic
contacts in vicinity of V580, H583 and W693
1 0 Major
d Carboxylate oxygens accepting from N542 0 1 Moderate
Table 4 Results obtained from RAW5000 conformers
Set or subset Ri (major) Ri (moderate) Ri (minor) Rtotal Seriously
misplaced
Rank,
best
Rank,
highest
PK5 0.6 – – 0.6 0 2 1
FABP 0.3, 0.6, 1.5, 1.7 – – 1.5 0 5 1
NEP 1.6, 0.4, 0.5 0.4 – 1.2 0 2 1
DHFR 0.4 1.3 0.2, 0.2 2.0 0 2 2
Chk1 0.5 1.2, 1.0 0.3, 2.1 1.2 0 1 1
NEU 0.7, 0.3 0.4 0.9, 0.6, 0.9 0.8 1 4 1
CA 1.3, 0.5 1.6, 1.6 1.4 1.8 2 4 4
ADA/1
a – 0.6, 0.5, 0.3, 0.7, 1.1 1.9 1.3 0 1 1
ADA/2 0.9, 0.7, 0.2, 1.3 0.2, 0.2 – 1.9 0 18 1
ADA/3 0.9, 0.8, 0.7, 1.7 0.1, 0.2 – 2.5 0 3 3
HSP/1 0.5, 0.7, 0.2 0.2, 0.2, 0.9 0.2 1.0 0 5 1
No satisfactory solutions were obtained for ADA, HSP, HSP/2; AChE, AChE/1, AChE/2
a Obtained by stepwise method
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other three have the acid groups superimposed (Fig. 6). The
occurrenceofclustersofsimilarsolutionsintheﬁlteredoutput
is a consequence of using a low ﬁltering dissimilarity
threshold (0.05), which tends to focus in on the most con-
vincing overlays at the expense of diversity. The optimum
value of this parameter may well vary from case to case,
depending, for example, on how many pharmacophore que-
ries the user wishes to generate.
Fatty acid binding protein
This is a simple set, the only challenge being to ﬁnd the
folded conformation of the C15 chain of the 2hnx ligand
that places it within the envelope of the other two ligands.
This is not very well achieved in the overlay generation
step, which tends to produce solutions like that shown at
the top of Fig. 7 (solutions from OPT5000 conformers tend
to be better). However, reﬁnement by annealing readily
ﬁxes the problem (Fig. 7, bottom). When applied to the
top-ranked solution, reﬁnement reduces an initial overlay
volume of 451 to 363 A ˚ 3, marginally lower than that of the
true overlay. A minor but understandable error in the
hydrogen-bond matching is that the carboxylate oxygens of
the 2hnx and 1tow ligands tend to be matched onto both the
hydroxyl oxygen and one of the pyrimidine nitrogens of the
1tou ligand. In fact, only the hydroxyl oxygen of the latter
ligand appears to hydrogen bond to the protein. It is not
uncommon for the algorithm to ﬁnd better matching of
hydrogen-bond groups than occurs in reality.
Figure 8 shows the top-ranked solution when the car-
bonyl oxygen of the 1tou ligand is constrained to super-
impose on carboxylate oxygen atoms of the other ligands.
This produces a fundamentally different, but still credible,
overlay. Constrained overlaying is an easy way to explore
speciﬁc overlay hypotheses.
Neprilysin
This set contains only four ligands, but they are ﬂexible
and feature rich and therefore moderately challenging to
Fig. 6 Two predictions for protein kinase 5 ligands. The top one is
similar to the true overlay, the bottom one is a credible alternative
with ligand acid groups overlaid Fig. 7 Top ranked solution for fatty acid binding protein ligands
before (top) and after (bottom) reﬁnement
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123overlay. The solutions are excellent. Eight of the top ten
solutions have essentially correct feature mappings, though
several involve different ligand conformations from those
seen in the crystal structure. There are invariably minor
errors in the vicinity of the zinc-binding groups but never
sufﬁcient to obscure their obvious signiﬁcance to binding.
The second-ranked solution has both correct mappings and
almost correct conformations (Fig. 9). Solution 9 is a dif-
ferent but credible overlay in which the thiolate of the 1y8j
ligand is matched with carboxylate oxygens from the other
ligands. Only a small minority of the top twenty solutions
look unconvincing.
The 1r1j and 1y8j ligands in this set were built in their
thiolate forms, since it was known that the sulfur atoms
coordinate zinc and are likely to be ionised. Solutions
generated from the unionised forms would probably have
been much poorer since the sulfur atoms would not have
been regarded as acceptors. In a genuine drug discovery
project, the quality of answers would therefore depend on
whether investigators were aware of the probable presence
of a zinc ion in the binding site of the target protein.
Dihydrofolate reductase
Results on this set are good. The critical requirement is to
generatethecorrectalignmentofheterocycles,inwhichsome
of the bicyclic systems are ﬂipped in order to achieve the
required matching of hydrogen bonding groups. The correct
heterocycle alignment ispresent inabout halfofthe solutions
thatsurvivedﬁltering.Mostoftheremaindercontainplausible
alternative alignments. The highest ranked solution with the
correct heterocycle alignment (solution 2) also has the amide
and carboxylate groups of the 1drf, 1hfr and 2dhf ligands
correctly superimposed and all six phenyl-ring centroids in
roughly the same position. In the true overlay, there is a dis-
tinct separation between the phenyl groups of the 1drf, 1hfr
and 2dhf ligands and those of the remaining ligands.
Although solution 2 has almost perfect feature match-
ing, it has incorrect ligand conformations (extended rather
than bent). This is typical for these ligands: prediction of
the correct feature matching is easily achieved but almost
always with extended conformations. Only with OPT5000
conformers can solutions be generated with ligand con-
formations similar to those seen in the crystal structures.
(This is probably due to the fact that the RAW5000 con-
formers do not contain good approximations of the binding
conformations of the 1drf and 2dhf ligands whereas the
OPT5000 conformer sets do.) However, the problem is
solved by overlay multiplication. Thus, when solution 2
was subjected to this process, both bent and extended
overlays with correct feature matching were produced.
Figure 3 shows the original solution 2 (top) and the top-
ranked solution from overlay multiplication, after reﬁne-
ment (bottom). The latter is close to the true overlay in both
feature matching and ligand conformations.
Checkpoint kinase
This set includes six very similar ligands (2br1, 2brb, 2brg,
2brh, 2brm, 2bro) but is otherwise quite diverse. Results
are very good. Most solutions are close to the true overlay
Fig. 8 Constrained overlay of fatty acid binding protein ligands
(carbon atoms of 1tou ligand shown in magenta)
Fig. 9 Second-ranked solution for neprilysin ligands (carbons col-
oured green) superimposed on true overlay (carbons in magenta)
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123and, in particular, the key pair of donor and acceptor
pharmacophore points is found, with all the correct donors
and acceptors from the individual ligands. It is to this set
that the plot shown in Fig. 4 pertains. The two large
clusters on the right of this plot comprise essentially correct
solutions, the difference between them being that one of
the ligands (1zys) is rotated by about 30  in one cluster
compared to the other. The two outliers on the left of the
plot correspond to a different and incorrect positioning of
the six similar ligands referred to above. In both correct
and outlier solutions, the CH groups at the 2-position of the
fused pyrimidine rings of these ligands are correctly placed
in the key donor cluster but, in the outliers, the six ligands
are ﬂipped so that the wrong pyrimidine nitrogen is placed
in the key acceptor cluster (Fig. 10). In addition, one of the
outliers also has another ligand (1zlt) misplaced, resulting
in a reasonable but incorrect matching. While the multi-
dimensional-scaling plots are not always useful, they can,
as in this case, highlight differences between overlays that
might otherwise be missed.
Neuraminidase
The ligands in this set are all very similar, each containing
a core substructure comprising a 6-membered ring with
para-related acid and amide (or lactam) substituents. It was
included in the validation to mimic the type of set that
might be overlaid in a 3D QSAR exercise. Although the
problem may appear trivial, it is not. Accepting that the
core substructures from the eleven ligands should be
superimposed, there are still many ways of achieving this.
Assume the ﬁrst ligand is placed arbitrarily. Since the bond
between the 6-membered ring and the amide or lactam
group is rotatable, the second and subsequent ligands may
each be superimposed on the ﬁrst in two ways whilst
keeping the core substructures well aligned, giving a total
of 2
10 possibilities for the complete overlay. With this in
mind, we were surprised to ﬁnd that several of the solu-
tions, including the top-ranked, have each molecule ‘‘the
right way round’’. This is particularly impressive as it
places two cationic (guanidinium) groups on one side of
the overlay and two (a guanidinium and ammonium) on the
other, a correct but perhaps surprising arrangement
(Fig. 11). The correct solution has a particularly low union
volume, which probably explains why it can be found so
readily.
The ligand from 1nsc cannot be placed optimally
because OMEGA does not generate the rather strained ring
conformation reported in the PDB structure. Instead, it
generates chair conformers with the carboxylate group
axial, meaning that this group is not superimposed on the
acid groups of the other ligands. This problem is found
with all the conformer sets.
Carbonic anhydrase
Theseligandsallcontainsulfonamideorsulfamategroupsthat
coordinatetheactive-sitezincatom.AlthoughtheRiandRtotal
valuesforthebestsolutionlookreasonable(Table 4),itisnota
particularlygoodprediction(Fig. 12).Themetal-coordinating
warheadsarecorrectlyoverlaid(thisistrueinallsolutions)and
thereisenoughofaclusterofacceptorstoindicatethepresence
of the partial pharmacophore point corresponding to interac-
tion with Gln92. The hydrophobic side chains of the 1bn3,
1bn4, 1bnq, 1if7, 1oq5, 1xpz, 1zh9 and 2hoc ligands are
overlaidaboutaswellasinthetrueoverlay(whichistosay,not
very), but in the wrong position (that is, the ligand conforma-
tions are different from those in the true overlay). The 1eou
Fig. 10 Top: the true overlay of the ligands from the checkpoint
kinase complexes 2br1, 2brb, 2brg, 2brh, 2brm, 2bro (carbons in
magenta) superimposed on the corresponding ligands from one of the
correct solutions obtained for the Chk1 test set (carbons in green,
remaining ligands in set omitted for clarity). Bottom: the same true
overlay superimposed on ligands 2br1… 2bro from one of the
incorrect outlier solutions. Both have the requisite clusters of donor
and acceptor atoms (shown as spheres) but the acceptor cluster in the
incorrect solution involves the wrong pyrimidine nitrogen
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123ligandis badly misplaced (as it is in all solutions). Overall, the
predictions for this set, while containing some of the charac-
teristics of the true overlay, add nothing to what is likely to be
discerned by a competent modeler, in contrast to the neur-
aminidase set, where we feel the program genuinely adds
value. Reﬁning the solutions arguably improves the situation
somewhat. We have no insight into why the algorithm ﬁnds
this setcomparatively difﬁcult, save to note that theperipheral
hydrophobicgroupsinthetrueoverlay(thoseremotefromthe
warhead groups) are not tightly overlaid.
Adenosine deaminase
The correct solution is not found for the complete set. An
obvious reason is that the ligand from the 1krm complex
adopts a binding mode that is drastically different from those
oftheotherligands.Whenthisligandisomitted(subsetADA/
1), correct solutions are still not generated by the standard
approach. All but two of the molecules in the subset are
chemically similar imidazoliums, and these are overlaid with
ease,butthecorrectpositioningoftheothertwoligands(1ndv
and 1wxy) remains elusive. The problem is that, in the true
overlay of the 1ndv and 1wxy ligands on any of the imi-
dazoliums(the1ndwligand,forexample;Fig. 13),thereisno
protein residue that hydrogen bonds to all three ligands and
the overlap of hydrophobic groups is poor. Thus, no base
tripletexistsfromwhich analignment ﬁngerprint can bebuilt
to generate the correct answer. The algorithm does ﬁnd
solutions acceptably close to the true overlay for subsets
comprising three of the larger imidazoliums and one or other
(butnotboth)ofthe1ndvand1wxyligands,forwhichsubsets
(ADA/2 and ADA/3) a common pharmacophore of size 3
exists in the true overlays.
The correct overlay for ADA/1 can be generated by the
stepwise approach. In our ﬁrst experiment, the imidazoli-
ums were overlaid without the 1ndv and 1wxy ligands. The
top 20 solutions were treated as ‘‘conformers’’ of a ‘‘su-
permolecule’’ and used as input to a second overlay-gen-
eration job in which the 1wxy ligand was introduced.
Finally, a third step was used to generate overlays involving
the 1ndv ligand. This produced solutions close to the true
overlay. Three other ordering strategies that seemed viable
were also tried (detailed in Supporting Information). The
results in Table 4 were obtained by ranking the pooled
solutions from the four separate stepwise experiments. The
top-ranked solution is similar to the true overlay.
Heat shock protein 90
The 10 ligands in this set may be divided into two groups:
(a) the closely similar pyrazole or isoxazole ligands of 1yc1,
1yc4, 2bsm, 2byi, 2bz5, 2cct, 2uwd together with the struc-
turallyunrelatedligandfrom2bz5;and(b)twopurineligands
(1byqand1uy8)andthemacrocyclicligandfrom1yet.Allthe
ligands donate to Asp93 and accept from Thr184 and/or a
conserved water molecule. However, the donor (D) and
acceptor(A) groupsinthe group b ligandshaveshorter D   A
distancesthanintheligandsofgroupa,potentiallymakingthe
results sensitive to the choice of triplet distance bins. More
seriously, the mouth of the binding cavity is rather large and
the ligands from the two groups occupy different parts of it,
resulting in poor volume overlap (Fig. 14). Consequently,
reasonable results are obtained for subset HSP/1 (containing
alltheligandsingroupa,butnonefromgroupb)butnotforthe
complete set of all ten ligands, or for subsets such as HSP/2
which involve ligands from both groups. An additional
problem with the HSP/2 subset is that many of the false
solutionsscorebetterthanthetrueoverlay(forexample,have
far lower union volumes and better matching of hydrogen-
bonding groups). Thus, it is not clear how the true overlay
could be recognised even if it were generated. We conclude
that this is a difﬁcult test set.
Fig. 11 At top, the true overlay of four of the neuraminidase ligands
(1a4g, 1a4q, 1b9t, 1inf); at bottom, the positions of the same ligands
in the best predicted overlay (remaining ligands in set omitted for
clarity). In both, two cationic groups (shown in ball-and-stick style)
lie on one side of the overlay and two on the other
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123Acetylcholinesterase
This is the only protein on which we were entirely unsuc-
cessful. No overlays at all (not even incorrect ones) can be
Fig. 12 True (left) and best
predicted overlay (right)o f
carbonic anhydrase ligands. In
the prediction, metal
coordinating groups are overlaid
correctly, and some of the
groups hydrogen bonding to
Gln92 are properly
superimposed (shown as
spheres), but hydrophobic
portions of the ligands are not
correctly positioned and the
1eou ligand (carbons in purple)
is badly misplaced. Overall, it is
a rather poor result
Fig. 13 True overlay of three adenosine deaminase ligands from
PDB complexes 1ndw, 1ndv and 1wxy (carbon atoms coloured in
green, magenta and orange, respectively)
Fig. 14 True overlay of ten heat shock protein ligands, showing the
poor volume overlap of three ligands (from PDB complexes 1byq,
1uy8, 1yet, coloured in magenta) with the remainder (1yc1, 1yc4,
2bsm, 2byi, 2bz5, 2cct, 2uwd, coloured in green)
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123generated for the complete set of eleven ligands because the
algorithm cannot ﬁnd any base triplet from which to con-
struct an alignment ﬁngerprint. The ligands from 2c5g and
1eve must be omitted (subset AChE/1) before any solutions
can be produced, but nothing close to the true answer is
found. The exceptional difﬁculty of the set may be
explained as follows. (a) Binding is almost entirely hydro-
phobic in nature. No protein atom forms hydrogen bonds to
more than three of the eleven ligands; several ligands form
only one hydrogen bond to the protein; and one (1eve)
forms no hydrogen bonds at all. Hydrophobic interactions
are much less directional than hydrogen bonds, so this
makes overlay prediction far harder. Further, most of the
ligands have donor groups, so the algorithm tends to ﬁnd
false solutions with partial donor pharmacophore points.
(b) The true overlay is in some respects less convincing than
some of the solutions produced by the algorithm. For
example, Fig. 15 shows the true and a predicted overlay for
the subset of large ligands, AChE/2. In the true overlay, the
heterocyclic systems in the vicinity of the AChE ‘‘periph-
eral binding site’’ (Trp279 and nearby residues) are much
less closely overlaid that in the prediction. (c) There are
signiﬁcant ligand-induced conformational changes to the
protein at Phe330, altering the space accessible to ligands.
Perhaps the biggest problem is that binding to AChE is
dominated by electrostatic attraction between the electron-
rich aromatic system of Trp84 and hydrophobic groups on
the ligands that are rendered electron deﬁcient by the
inductive effect of nearby positive centres (all the ligands
can safely be assumed to be cations). This type of
electropositive hydrophobe is not speciﬁcally represented
in our feature-typing scheme. Possibly, the set may be
more amenable to ﬁeld-based overlay methods [40].
Inﬂuence of conformer input; computational
requirements
Results obtained from the other conformer sets were
inspected in sufﬁcient detail to enable qualitative conclu-
sionstobedrawn.Optimisingthegeometryofthemolecular
models from which OMEGA generates conformers has
variable effects. For DHFR, it is advantageous, since the
geometryoptimisationallowssolutionstobefoundthathave
correctfeaturemappingsandligandconformationssimilarto
those seen in the true overlay. In contrast, solutions gener-
ated from unoptimised starting points often have correct
feature mappings but invariably with incorrect ligand con-
formations. For neuraminidase, however, optimisation was
counter-productive, since it produced a poor geometry for
the ligand from 1vcj, making it difﬁcult to place correctly.
There seems to be a gradual improvement in results as
the number of conformers is increased, but the effect is
small. For example, the RAW200 set yields results for PK5,
FABP, NEP, DHFR and Chk1 that are of are comparable
quality to those obtained from the RAW5000 set, while the
overlays for NEU are nearly as good. Computation times
decrease dramatically for some sets as the number of con-
formers is reduced; example ﬁgures are given in Table 5.
Memory requirements, which can be over a gigabyte in
some cases, are also appreciably reduced by decreasing the
number of input conformers. The faster speeds obtainable
by using the smaller conformer sets probably outweigh any
consequential loss in solution quality.
Sensitivity of results to scoring functions
The hydrogen bond and hydrophobic scoring functions
involve several empirical parameters and we wished to
Fig. 15 True overlay (left) and top-ranked prediction (right) for a
subset of acetylcholinesterase ligands (1h23, 1w4l, 1zgb, 2ckm). The
heterocyclic systems at the top are more closely aligned in the
prediction than in the true overlay
Table 5 Computation times (minutes) as a function of maximum
number of conformers per ligand (based on RAW conformer sets)
Maximum number of conformers per ligand
Sets 5000 1000 200
NEP 38.4 19.8 4.2
DHFR 17.5 11.0 3.5
Chk1 2.8 2.6 1.8
NEU 3.6 3.6 3.4
CA 4.9 4.8 2.7
ADA 52.2 16.2 5.4
Elapsed times for overlay generation and ﬁltering on an Intel T7500
2.2 GHz processor, excluding time required for conformer generation
but including solution analysis
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123establish whether simpler functions might be adequate.
Accordingly, we repeated the RAW5000 validation,
replacing the hydrogen-bond score of Eq. (1) with the
function:
HBðsimpleÞ¼RA2
p ð7Þ
where the summation is over the clusters of donor atoms
and acceptor atoms in the overlay, and Ap is the number of
atoms in the pth such cluster. Similarly, the hydrophobic
score was computed as:
HYðsimpleÞ¼RH2
p ð8Þ
where the summation is over the clusters of hydrophobic
groups in the overlay, and Hp is the number of hydrophobes
in the pth such cluster. All other aspects of the methodol-
ogy were unchanged. The results obtained were nearly as
good as those described above (see Supporting Informa-
tion), the only substantive difference being that the correct
solution was no longer reliably obtained for ADA/1 using
the stepwise method. We still prefer the more complicated
functions because the score contributions made by indi-
vidual clusters make more sense when these functions are
used. For example, a buried cluster of hydrogen-bonding
atoms in the true overlay of neuraminidase ligands gets a
poor score contribution from Eq. (1) but a much larger
contribution if (7) is used. The former is intuitively more
reasonable and, in fact, the hydrogen-bonding atoms in
question do not interact with the protein. Nevertheless, it is
interesting that the simple functions perform so well.
Conclusions
The alignment ﬁngerprints described above have several
useful characteristics. Each bit is set according to the pres-
ence or absence of a particular type of chemical feature at or
near to a particular position in Cartesian space, when con-
formersarealignedinaconsistentframeofreferencedeﬁned
by a triplet pharmacophore known to be present in all con-
formerscontributingtotheﬁngerprint.Thisisdifferentfrom
pharmacophore ﬁngerprint techniques that assign bits
according to the presence or absence of a pair of features
separated by a particular distance [1]. The use of Cartesian-
based ﬁngerprints avoids the necessity of performing clique
detectiontoconﬁrmthepresenceofapharmacophore,astep
that is usually required when distance-based ﬁngerprints are
used. Every overlay generated from a ﬁngerprint is guaran-
teed to have at least three full pharmacophore points, cor-
respondingtothebasetriplet.Themethodtakesintoaccount
partial as well as full pharmacophore points and is sensitive
to whether two features in different molecules are exactly
aligned (map to the same grid point) or only closely aligned
(map to adjacent grid points). The B score calculated from
the ﬁngerprint correlates reasonably well with our more
accuratehydrogenbondandvolumescores,butisveryquick
to compute, allowing a large number of trial conformer
combinationstobetested.Thealgorithmlendsitselfeasilyto
constrained overlay generation.
In the validation, the algorithm performed well when the
true overlay contained at least three full pharmacophore
points. Thus, good results were obtained for the test sets
PK5, FABP, NEP, DHFR, Chk1, NEU, ADA/2 and ADA/3:
a high-ranking solution with the correct feature mappings
and ligand conformations close to those seen in the PDB
structures was almost always found. Results for CA (where
the true overlay has the requisite 3 full pharmacophore
points) were less good: the major features of the true
overlay were predicted adequately but minor details were
not reliably reproduced. For DHFR, solutions with correct
feature mappings were easily found but tended to have
incorrect ligand conformations. However, overlay multi-
plication was effective in ﬁnding alternative overlays with
the same mappings but different conformations, including
conformations similar to those in the crystal structures.
When the true overlay of a set of ligands did not contain
three full pharmacophore points, the algorithm often per-
formed poorly. This is sometimes understandable. For
example, the binding of the 1krm ligand in the ADA set is
very different from that of the other ligands. Similar situa-
tions occur in HSP with the 1byq, 1uy8 and 1yet ligands,
and in AChE, where the binding of the 1eve ligand is idi-
osyncratic. Sometimes, false solutions look more convinc-
ing than the true overlay (for example, for the subsets HSP/
2, AChE/2). If the true overlay looks unconvincing, it is
likely to be overlooked by users even if it can be generated.
In the ADA/1 ligand set, however, the true overlay looks
convincing even though it does not have three full pharma-
cophorepoints.Here,wewereabletoﬁndthecorrectsolution
bya stepwiseapproach.Thisisanimportantproof ofconcept
since it signiﬁcantly extends the range of problems on which
the algorithm might be successful (the use of ﬁtting points on
hydrophobenormalscanalsoachievethis,sinceitcanmakea
common pharmacophore of size 2 ‘‘look like’’ one of size 3).
Currently, a limitation of the stepwise approach is that the
user must choose manually the order in which the overlay is
pieced together. This is probably not as hard as it sounds
because it may often be obvious which ligands are causing
difﬁculty, and the simple strategy of leaving these ligands to
the end of the stepwise process may be successful, as it was
for ADA/1. Nevertheless, an automated way of selecting the
order in which ligands are introduced in stepwise overlay
generation is an important goal for the future, as are a further
investigation of the inﬂuence of the input conformer sets,
validation against more test sets, and a systematic optimisa-
tion of program parameters.
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